Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial

This work was supported by a grant from Pfizer (no grant number), which also provided palbociclib. Pfizer had no role in the management of this trial. All decisions and responsibilities for the trial were managed solely by the sponsor, the SOLTI Group.

Detalles Bibliográficos
Autores: Pascual, T., Villacampa Javierre, Guillermo, Oliveira, Mafalda, Escrivá-de-Romaní, S., Pernas, S., Paré, L., Adamo, Barbara, Cortés, J., Perelló, A., Galán, M., Melé, Mireia, Villanueva, L., González-Rodríguez, Marta, Tolosa, Pablo, Gonzalez-Farre, Blanca, Galván, Patricia, Canes, Jordi, Nuciforo, Paolo, Ferrero-Cafiero, Juan Manuel, Gonzàlez Farré, Xavier, Villagrasa-Gonzalez, Patricia, Prat, Aleix, Ciruelos, Eva
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:20.500.12328/5114
Acceso en línea:http://hdl.handle.net/20.500.12328/5114
https://dx.doi.org/10.1016/j.esmoop.2025.105572
Access Level:acceso abierto
Palabra clave:Metastatic breast cancer
HR-positive/HERC-positive
Palbociclib
Trastuzumab
Biomarkers
Gene expression profiling
Cáncer de mama metastásico
Biomarcadores
Perfil de expresión genética
Càncer de mama metastàsico
Biomarcadors
Perfil d'expressió genètica
616
Descripción
Sumario:This work was supported by a grant from Pfizer (no grant number), which also provided palbociclib. Pfizer had no role in the management of this trial. All decisions and responsibilities for the trial were managed solely by the sponsor, the SOLTI Group.

Similares en LA Referencia